Getting closer to personalised medicine in AS, ECM-mediated biomarkers may help predict response to Adalimumab in AS. The biomarkers C1M, C6M and PRO-C4 were lower in responders to adalimumab treatment after 24 weeks @RheumNow #ACR21 Abst#0915 https://t.co/K2YxPvUAwu https://t.co/w9kcBSFeG9

Interesting study. 79 nr-axSpA pts observed for 6 years. Every 2 yrs approximately 10% of pts progressed from nr-axSpA to AS! Next step: evaluate dz characteristics and determine potential at risk pts. Abs 0907 #ACR21 #RheumNow @RheumNow https://t.co/aRjXWjkVKg https://t.co/BiHFgDR8Kv

Abst0898 #ACR21 @RheumNow MRI findings of Vertebral Corner Inflammation & Vertebral Corner Fat Deposition associated w/syndesmophyte formation 2 y later, ORs 1.87-2.58 for various VCI/VCFD patterns. Protection against syndesmophyte seen if both VCI and VCFD were absent (OR 0.35) https://t.co/t01nxdEwON

Younger patients and African Americans have a high no show rate. Need to focus on high-risk individuals and improve access to new patient appointments. @rheumnow #ACR21 abst#0610 https://t.co/3XZmXWfili

Monozygotic twin study in PsO patients showed a gut and skin microbiome difference compared to their "normal" twin ⭐️Ruminococcus decreased/absent in gut flora of PsO ⭐️microbiome differences even in healthy PsO skin Abs#944 #ACR21 @RheumNow #ACRBest https://t.co/VlfVh5Kt3Y https://t.co/W0eSqi77lx

This slide 👇 from Dr. Mary Crow's lecture shows how 2 categories of autoantibodies with their distinct functions can allow for different therapeutic targets in #lupus @RheumNow #ACR21 #rheumatology https://t.co/wkthvj21cE

There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI

#ACR21 Hench Lecture. Wonderful talks by Peggy Crow on #lupus pathogenesis. Tour de force since LE cells discovery. Potential sources of self-nucleic acids: 💠Endogeneous retroelements LINE-1 💠Mitochondria 💠Cell-derived nuclear debris (NETs, apoptotic) @RheumNow https://t.co/TSdyqblYaA

Do you have trouble with no shows? Study out of Allegheny Health showed younger and black patients were among characteristics of pts at risk for new pt exam no shows. How can we do better for these pts? Thoughts? Abs 0610 #ACR21 #RheumNow @RheumNow https://t.co/MUcQarwvm6 https://t.co/Mue6By5mOV

In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/symptom improvement compared to those w/ late dz. IV GLM better overall regardless of dz duration. Abs 0912 #ACR21 #RheumNow @RheumNow https://t.co/S2L97c7oQO https://t.co/XXpveRwwmQ

Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy